- Home
- NPCT
as 05-13-2025 4:00pm EST
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 284.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 107.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Monthly | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $8.58 - $10.63 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Nuveen Core Plus Impact Fund of Beneficial Interest News
NPCT Breaking Stock News: Dive into NPCT Ticker-Specific Updates for Smart Investing
CNW Group
a year ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
a year ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
a year ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
a year ago
New Zealand scraps plan to tax livestock burps, farts
The Wall Street Journal
a year ago
ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
Business Wire
a year ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
Bloomberg
a year ago
UK Unemployment Rises in Sign Inflationary Pressures Cool
Simply Wall St.
a year ago
Insider-Owned Growth Companies On The Chinese Exchange In June 2024
Compare NPCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NPCT Nuveen Core Plus Impact Fund of Beneficial Interest - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.